The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.

Related Articles

The effect of TMEFF2 methylation on the tumor stage and survival outcome of clear cell renal cell carcinoma.

Cancer Biomark. 2017;19(2):207-212

Authors: Chen E, Zheng F, Yuan X, Ye Y, Li X, Dai Y, Chen L

Abstract
AIM: This study aimed to investigate the methylation status of EGF-like and two follistatin-like domains 2 (TMEFF2) promoter and its correlation with tumor stage and survival outcome in renal cell carcinoma (RCC).
MATERIALS AND METHODS: Paraffin-embedded specimens from 42 RCC patients were analyzed for TMEFF2 methylation by methylation-specific polymerase chain reaction. The distribution of TNM/AJCC stages and survival time were compared among patients with unmethylated and methylated TMEFF2.
RESULTS: There were 25 (59.5%) and 17 (40.5%) cases with methylated (M group) and unmethylated (M group) TMEFF2, respectively. There were more early-stage cancer patients in U group than in M group. Kaplan-Meier survival analysis showed that U group had a better but not significant survival outcome than M group (P = 0.123).
CONCLUSION: These findings showed that TMEFF2 methylation is not rare in RCC, and methylation may play an important role in the tumorigenesis of ccRCC.

PMID: 28128743 [PubMed - indexed for MEDLINE]

https://ift.tt/2E8weBh